← 產業報告目錄

Nanopharmaceuticals Industry Research Report 2026

出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-08頁數 143報告編號 APO-ded52334d3

授權報價

Single User$2,950 USD
Multi User$4,430 USD
Enterprise$5,900 USD
洽詢購買 申請 Sample

報告摘要

Nanopharmaceuticals are colloidal particles of 10 to 1,000 nanometers (1 micron) in size. They are widely used in drug delivery. Nanopharmaceuticals are diverse both in their shape and composition and often offer an advantage as compared to their “bulk” counterparts primarily because of size. There are two types of nanopharmaceuticals: (1) those where the therapeutic molecules are themselves the drug (i.e.,the therapeutic compound itself also functions as its own carrier); and (2) those where the therapeutic molecules are directly coupled (functionalized, entrapped, or coated) to a nanoparticle carrier. USA is the largest Nanopharmaceuticals market with about 59% market share. Europe is follower, accounting for about 33% market share. The key players are Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, Celgene, Novavax, Stryker, Gilead Sciences, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Pharma, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma, Navidea Biopharmaceuticals, Lummy etc. Top 3 companies occupied about 34% market share. Report Scope This report quantifies the global Nanopharmaceuticals market in terms of revenue (US$ million) and, where applicable, sales volume (K MT), using 2025 as the base year and providing annual historical and forecast data for 2021–2032. It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K MT) and concentration ratios (CR5/CR10). The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems. Key Companies & Market Share Insights This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking. Nanopharmaceuticals Market by Company Merck Pfizer Novartis Abbott GlaxoSmithKline Roche Sanofi Eli Lilly Astrazeneca Johnson & Johnson Celgene Novavax Stryker Gilead Sciences OSI Pharmaceuticals Kadmon Pharmaceuticals Samyang Biopharm Mitsubishi Pharma Kaken Pharmaceutical Selecta Biosciences Par Pharmaceutical Cerulean Pharma Navidea Biopharmaceuticals Lummy Nanopharmaceuticals Segment by Type Liposomes Polymeric Micelles Solid Lipid Nanoparticles Microemulsion and Nnanoemulsion Nanosuspension Nanopharmaceuticals Segment by Application Cancer and Tumor Autoimmune Disorders Inflammation Others Nanopharmaceuticals Segment by Region North America United States Canada Mexico Europe Germany France U.K. Italy Russia Spain Netherlands Switzerland Sweden Poland Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Middle East & Africa Egypt South Africa Israel Türkiye GCC Countries Key Drivers & Barriers High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects. Reasons to Buy This Report 1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nanopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market. 2. This report will help stakeholders to understand the global industry status and trends of Nanopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities. 3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition. 4. This report stays updated with novel technology integration, features, and the latest developments in the market 5. This report helps stakeholders to gain insights into which regions to target globally 6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nanopharmaceuticals. 7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution. Chapter Outline Chapter 1: Research objectives, research methods, data sources, data cross-validation; Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term. Chapter 3: Detailed analysis of Nanopharmaceuticals manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc. Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc. Chapter 5: Production/output, value of Nanopharmaceuticals by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years. Chapter 6: Consumption of Nanopharmaceuticals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world. Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 11: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface 1.1 Scope of Report 1.2 Reasons for Doing This Study 1.3 Research Methodology 1.4 Research Process 1.5 Data Source 1.5.1 Secondary Sources 1.5.2 Primary Sources 2 Market Overview 2.1 Product Definition 2.2 Global Market Growth Prospects 2.2.1 Global Nanopharmaceuticals Market Size (2021-2032) 2.2.2 Global Nanopharmaceuticals Sales (2021-2032) 2.2.3 Global Nanopharmaceuticals Market Average Price (2021-2032) 2.3 Nanopharmaceuticals by Type 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) 2.3.2 Liposomes 2.3.3 Polymeric Micelles 2.3.4 Solid Lipid Nanoparticles 2.3.5 Microemulsion and Nnanoemulsion 2.3.6 Nanosuspension 2.4 Nanopharmaceuticals by Application 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) 2.4.2 Cancer and Tumor 2.4.3 Autoimmune Disorders 2.4.4 Inflammation 2.4.5 Others 3 Market Competitive Landscape by Manufacturers 3.1 Global Nanopharmaceuticals Market Competitive Situation by Manufacturers (2021 Versus 2025) 3.2 Global Nanopharmaceuticals Sales (K MT) of Manufacturers (2021-2026) 3.3 Global Nanopharmaceuticals Revenue of Manufacturers (2021-2026) 3.4 Global Nanopharmaceuticals Average Price by Manufacturers (2021-2026) 3.5 Global Nanopharmaceuticals Industry Ranking, 2024 VS 2025 VS 2026 3.6 Global Manufacturers of Nanopharmaceuticals, Manufacturing Sites & Headquarters 3.7 Global Manufacturers of Nanopharmaceuticals, Product Type & Application 3.8 Global Manufacturers of Nanopharmaceuticals, Established Date 3.9 Global Nanopharmaceuticals Market CR5 and HHI 3.10 Global Manufacturers Mergers & Acquisition 4 Manufacturers Profiled 4.1 Merck 4.1.1 Merck Company Information 4.1.2 Merck Business Overview 4.1.3 Merck Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.1.4 Merck Nanopharmaceuticals Product Portfolio 4.1.5 Merck Recent Developments 4.2 Pfizer 4.2.1 Pfizer Company Information 4.2.2 Pfizer Business Overview 4.2.3 Pfizer Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.2.4 Pfizer Nanopharmaceuticals Product Portfolio 4.2.5 Pfizer Recent Developments 4.3 Novartis 4.3.1 Novartis Company Information 4.3.2 Novartis Business Overview 4.3.3 Novartis Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.3.4 Novartis Nanopharmaceuticals Product Portfolio 4.3.5 Novartis Recent Developments 4.4 Abbott 4.4.1 Abbott Company Information 4.4.2 Abbott Business Overview 4.4.3 Abbott Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.4.4 Abbott Nanopharmaceuticals Product Portfolio 4.4.5 Abbott Recent Developments 4.5 GlaxoSmithKline 4.5.1 GlaxoSmithKline Company Information 4.5.2 GlaxoSmithKline Business Overview 4.5.3 GlaxoSmithKline Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.5.4 GlaxoSmithKline Nanopharmaceuticals Product Portfolio 4.5.5 GlaxoSmithKline Recent Developments 4.6 Roche 4.6.1 Roche Company Information 4.6.2 Roche Business Overview 4.6.3 Roche Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.6.4 Roche Nanopharmaceuticals Product Portfolio 4.6.5 Roche Recent Developments 4.7 Sanofi 4.7.1 Sanofi Company Information 4.7.2 Sanofi Business Overview 4.7.3 Sanofi Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.7.4 Sanofi Nanopharmaceuticals Product Portfolio 4.7.5 Sanofi Recent Developments 4.8 Eli Lilly 4.8.1 Eli Lilly Company Information 4.8.2 Eli Lilly Business Overview 4.8.3 Eli Lilly Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.8.4 Eli Lilly Nanopharmaceuticals Product Portfolio 4.8.5 Eli Lilly Recent Developments 4.9 Astrazeneca 4.9.1 Astrazeneca Company Information 4.9.2 Astrazeneca Business Overview 4.9.3 Astrazeneca Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.9.4 Astrazeneca Nanopharmaceuticals Product Portfolio 4.9.5 Astrazeneca Recent Developments 4.10 Johnson & Johnson 4.10.1 Johnson & Johnson Company Information 4.10.2 Johnson & Johnson Business Overview 4.10.3 Johnson & Johnson Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.10.4 Johnson & Johnson Nanopharmaceuticals Product Portfolio 4.10.5 Johnson & Johnson Recent Developments 4.11 Celgene 4.11.1 Celgene Company Information 4.11.2 Celgene Business Overview 4.11.3 Celgene Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.11.4 Celgene Nanopharmaceuticals Product Portfolio 4.11.5 Celgene Recent Developments 4.12 Novavax 4.12.1 Novavax Company Information 4.12.2 Novavax Business Overview 4.12.3 Novavax Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.12.4 Novavax Nanopharmaceuticals Product Portfolio 4.12.5 Novavax Recent Developments 4.13 Stryker 4.13.1 Stryker Company Information 4.13.2 Stryker Business Overview 4.13.3 Stryker Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.13.4 Stryker Nanopharmaceuticals Product Portfolio 4.13.5 Stryker Recent Developments 4.14 Gilead Sciences 4.14.1 Gilead Sciences Company Information 4.14.2 Gilead Sciences Business Overview 4.14.3 Gilead Sciences Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.14.4 Gilead Sciences Nanopharmaceuticals Product Portfolio 4.14.5 Gilead Sciences Recent Developments 4.15 OSI Pharmaceuticals 4.15.1 OSI Pharmaceuticals Company Information 4.15.2 OSI Pharmaceuticals Business Overview 4.15.3 OSI Pharmaceuticals Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.15.4 OSI Pharmaceuticals Nanopharmaceuticals Product Portfolio 4.15.5 OSI Pharmaceuticals Recent Developments 4.16 Kadmon Pharmaceuticals 4.16.1 Kadmon Pharmaceuticals Company Information 4.16.2 Kadmon Pharmaceuticals Business Overview 4.16.3 Kadmon Pharmaceuticals Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.16.4 Kadmon Pharmaceuticals Nanopharmaceuticals Product Portfolio 4.16.5 Kadmon Pharmaceuticals Recent Developments 4.17 Samyang Biopharm 4.17.1 Samyang Biopharm Company Information 4.17.2 Samyang Biopharm Business Overview 4.17.3 Samyang Biopharm Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.17.4 Samyang Biopharm Nanopharmaceuticals Product Portfolio 4.17.5 Samyang Biopharm Recent Developments 4.18 Mitsubishi Pharma 4.18.1 Mitsubishi Pharma Company Information 4.18.2 Mitsubishi Pharma Business Overview 4.18.3 Mitsubishi Pharma Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.18.4 Mitsubishi Pharma Nanopharmaceuticals Product Portfolio 4.18.5 Mitsubishi Pharma Recent Developments 4.19 Kaken Pharmaceutical 4.19.1 Kaken Pharmaceutical Company Information 4.19.2 Kaken Pharmaceutical Business Overview 4.19.3 Kaken Pharmaceutical Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.19.4 Kaken Pharmaceutical Nanopharmaceuticals Product Portfolio 4.19.5 Kaken Pharmaceutical Recent Developments 4.20 Selecta Biosciences 4.20.1 Selecta Biosciences Company Information 4.20.2 Selecta Biosciences Business Overview 4.20.3 Selecta Biosciences Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.20.4 Selecta Biosciences Nanopharmaceuticals Product Portfolio 4.20.5 Selecta Biosciences Recent Developments 4.21 Par Pharmaceutical 4.21.1 Par Pharmaceutical Company Information 4.21.2 Par Pharmaceutical Business Overview 4.21.3 Par Pharmaceutical Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.21.4 Par Pharmaceutical Nanopharmaceuticals Product Portfolio 4.21.5 Par Pharmaceutical Recent Developments 4.22 Cerulean Pharma 4.22.1 Cerulean Pharma Company Information 4.22.2 Cerulean Pharma Business Overview 4.22.3 Cerulean Pharma Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.22.4 Cerulean Pharma Nanopharmaceuticals Product Portfolio 4.22.5 Cerulean Pharma Recent Developments 4.23 Navidea Biopharmaceuticals 4.23.1 Navidea Biopharmaceuticals Company Information 4.23.2 Navidea Biopharmaceuticals Business Overview 4.23.3 Navidea Biopharmaceuticals Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.23.4 Navidea Biopharmaceuticals Nanopharmaceuticals Product Portfolio 4.23.5 Navidea Biopharmaceuticals Recent Developments 4.24 Lummy 4.24.1 Lummy Company Information 4.24.2 Lummy Business Overview 4.24.3 Lummy Nanopharmaceuticals Sales, Revenue and Gross Margin (2021-2026) 4.24.4 Lummy Nanopharmaceuticals Product Portfolio 4.24.5 Lummy Recent Developments 5 Global Nanopharmaceuticals Market Scenario by Region 5.1 Global Nanopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032 5.2 Global Nanopharmaceuticals Sales by Region: 2021-2032 5.2.1 Global Nanopharmaceuticals Sales by Region: 2021-2026 5.2.2 Global Nanopharmaceuticals Sales by Region: 2027-2032 5.3 Global Nanopharmaceuticals Revenue by Region: 2021-2032 5.3.1 Global Nanopharmaceuticals Revenue by Region: 2021-2026 5.3.2 Global Nanopharmaceuticals Revenue by Region: 2027-2032 5.4 North America Nanopharmaceuticals Market Facts & Figures by Country 5.4.1 North America Nanopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 5.4.2 North America Nanopharmaceuticals Sales by Country (2021-2032) 5.4.3 North America Nanopharmaceuticals Revenue by Country (2021-2032) 5.4.4 United States 5.4.5 Canada 5.4.6 Mexico 5.5 Europe Nanopharmaceuticals Market Facts & Figures by Country 5.5.1 Europe Nanopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 5.5.2 Europe Nanopharmaceuticals Sales by Country (2021-2032) 5.5.3 Europe Nanopharmaceuticals Revenue by Country (2021-2032) 5.5.4 Germany 5.5.5 France 5.5.6 U.K. 5.5.7 Italy 5.5.8 Russia 5.5.9 Spain 5.5.10 Netherlands 5.5.11 Switzerland 5.5.12 Sweden 5.5.13 Poland 5.6 Asia Pacific Nanopharmaceuticals Market Facts & Figures by Country 5.6.1 Asia Pacific Nanopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 5.6.2 Asia Pacific Nanopharmaceuticals Sales by Country (2021-2032) 5.6.3 Asia Pacific Nanopharmaceuticals Revenue by Country (2021-2032) 5.6.4 China 5.6.5 Japan 5.6.6 South Korea 5.6.7 India 5.6.8 Australia 5.6.9 Taiwan 5.6.10 Southeast Asia 5.7 South America Nanopharmaceuticals Market Facts & Figures by Country 5.7.1 South America Nanopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 5.7.2 South America Nanopharmaceuticals Sales by Country (2021-2032) 5.7.3 South America Nanopharmaceuticals Revenue by Country (2021-2032) 5.7.4 Brazil 5.7.5 Argentina 5.7.6 Chile 5.8 Middle East and Africa Nanopharmaceuticals Market Facts & Figures by Country 5.8.1 Middle East and Africa Nanopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 5.8.2 Middle East and Africa Nanopharmaceuticals Sales by Country (2021-2032) 5.8.3 Middle East and Africa Nanopharmaceuticals Revenue by Country (2021-2032) 5.8.4 Egypt 5.8.5 South Africa 5.8.6 Israel 5.8.7 Türkiye 5.8.8 GCC Countries 6 Segment by Type 6.1 Global Nanopharmaceuticals Sales by Type (2021-2032) 6.1.1 Global Nanopharmaceuticals Sales by Type (2021-2032) & (K MT) 6.1.2 Global Nanopharmaceuticals Sales Market Share by Type (2021-2032) 6.2 Global Nanopharmaceuticals Revenue by Type (2021-2032) 6.2.1 Global Nanopharmaceuticals Sales by Type (2021-2032) & (US$ Million) 6.2.2 Global Nanopharmaceuticals Revenue Market Share by Type (2021-2032) 6.3 Global Nanopharmaceuticals Price by Type (2021-2032) 7 Segment by Application 7.1 Global Nanopharmaceuticals Sales by Application (2021-2032) 7.1.1 Global Nanopharmaceuticals Sales by Application (2021-2032) & (K MT) 7.1.2 Global Nanopharmaceuticals Sales Market Share by Application (2021-2032) 7.2 Global Nanopharmaceuticals Revenue by Application (2021-2032) 7.2.1 Global Nanopharmaceuticals Sales by Application (2021-2032) & (US$ Million) 7.2.2 Global Nanopharmaceuticals Revenue Market Share by Application (2021-2032) 7.3 Global Nanopharmaceuticals Price by Application (2021-2032) 8 Value Chain and Sales Channels Analysis of the Market 8.1 Nanopharmaceuticals Value Chain Analysis 8.1.1 Nanopharmaceuticals Key Raw Materials 8.1.2 Raw Materials Key Suppliers 8.1.3 Nanopharmaceuticals Production Mode & Process 8.2 Nanopharmaceuticals Sales Channels Analysis 8.2.1 Direct Comparison with Distribution Share 8.2.2 Nanopharmaceuticals Distributors 8.2.3 Nanopharmaceuticals Customers 9 Global Nanopharmaceuticals Analyzing Market Dynamics 9.1 Nanopharmaceuticals Industry Trends 9.2 Nanopharmaceuticals Industry Drivers 9.3 Nanopharmaceuticals Industry Opportunities and Challenges 9.4 Nanopharmaceuticals Industry Restraints 10 Report Conclusion 11 Disclaimer
圖表清單 List of Tables & Figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Nanopharmaceuticals Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Nanopharmaceuticals Sales (K MT) of Manufacturers (2021-2026) Table 7. Global Nanopharmaceuticals Sales Market Share by Manufacturers (2021-2026) Table 8. Global Nanopharmaceuticals Revenue of Manufacturers (2021-2026) Table 9. Global Nanopharmaceuticals Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Nanopharmaceuticals Average Price (USD/MT) of Manufacturers (2021-2026) Table 11. Global Nanopharmaceuticals Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Nanopharmaceuticals, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Nanopharmaceuticals, Product Type & Application Table 14. Global Nanopharmaceuticals Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Nanopharmaceuticals by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Merck Company Information Table 19. Merck Business Overview Table 20. Merck Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 21. Merck Nanopharmaceuticals Product Portfolio Table 22. Merck Recent Developments Table 23. Pfizer Company Information Table 24. Pfizer Business Overview Table 25. Pfizer Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 26. Pfizer Nanopharmaceuticals Product Portfolio Table 27. Pfizer Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 31. Novartis Nanopharmaceuticals Product Portfolio Table 32. Novartis Recent Developments Table 33. Abbott Company Information Table 34. Abbott Business Overview Table 35. Abbott Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 36. Abbott Nanopharmaceuticals Product Portfolio Table 37. Abbott Recent Developments Table 38. GlaxoSmithKline Company Information Table 39. GlaxoSmithKline Business Overview Table 40. GlaxoSmithKline Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 41. GlaxoSmithKline Nanopharmaceuticals Product Portfolio Table 42. GlaxoSmithKline Recent Developments Table 43. Roche Company Information Table 44. Roche Business Overview Table 45. Roche Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 46. Roche Nanopharmaceuticals Product Portfolio Table 47. Roche Recent Developments Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 51. Sanofi Nanopharmaceuticals Product Portfolio Table 52. Sanofi Recent Developments Table 53. Eli Lilly Company Information Table 54. Eli Lilly Business Overview Table 55. Eli Lilly Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 56. Eli Lilly Nanopharmaceuticals Product Portfolio Table 57. Eli Lilly Recent Developments Table 58. Astrazeneca Company Information Table 59. Astrazeneca Business Overview Table 60. Astrazeneca Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 61. Astrazeneca Nanopharmaceuticals Product Portfolio Table 62. Astrazeneca Recent Developments Table 63. Johnson & Johnson Company Information Table 64. Johnson & Johnson Business Overview Table 65. Johnson & Johnson Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 66. Johnson & Johnson Nanopharmaceuticals Product Portfolio Table 67. Johnson & Johnson Recent Developments Table 68. Celgene Company Information Table 69. Celgene Business Overview Table 70. Celgene Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 71. Celgene Nanopharmaceuticals Product Portfolio Table 72. Celgene Recent Developments Table 73. Novavax Company Information Table 74. Novavax Business Overview Table 75. Novavax Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 76. Novavax Nanopharmaceuticals Product Portfolio Table 77. Novavax Recent Developments Table 78. Stryker Company Information Table 79. Stryker Business Overview Table 80. Stryker Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 81. Stryker Nanopharmaceuticals Product Portfolio Table 82. Stryker Recent Developments Table 83. Gilead Sciences Company Information Table 84. Gilead Sciences Business Overview Table 85. Gilead Sciences Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 86. Gilead Sciences Nanopharmaceuticals Product Portfolio Table 87. Gilead Sciences Recent Developments Table 88. OSI Pharmaceuticals Company Information Table 89. OSI Pharmaceuticals Business Overview Table 90. OSI Pharmaceuticals Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 91. OSI Pharmaceuticals Nanopharmaceuticals Product Portfolio Table 92. OSI Pharmaceuticals Recent Developments Table 93. Kadmon Pharmaceuticals Company Information Table 94. Kadmon Pharmaceuticals Business Overview Table 95. Kadmon Pharmaceuticals Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 96. Kadmon Pharmaceuticals Nanopharmaceuticals Product Portfolio Table 97. Kadmon Pharmaceuticals Recent Developments Table 98. Samyang Biopharm Company Information Table 99. Samyang Biopharm Business Overview Table 100. Samyang Biopharm Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 101. Samyang Biopharm Nanopharmaceuticals Product Portfolio Table 102. Samyang Biopharm Recent Developments Table 103. Mitsubishi Pharma Company Information Table 104. Mitsubishi Pharma Business Overview Table 105. Mitsubishi Pharma Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 106. Mitsubishi Pharma Nanopharmaceuticals Product Portfolio Table 107. Mitsubishi Pharma Recent Developments Table 108. Kaken Pharmaceutical Company Information Table 109. Kaken Pharmaceutical Business Overview Table 110. Kaken Pharmaceutical Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 111. Kaken Pharmaceutical Nanopharmaceuticals Product Portfolio Table 112. Kaken Pharmaceutical Recent Developments Table 113. Selecta Biosciences Company Information Table 114. Selecta Biosciences Business Overview Table 115. Selecta Biosciences Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 116. Selecta Biosciences Nanopharmaceuticals Product Portfolio Table 117. Selecta Biosciences Recent Developments Table 118. Par Pharmaceutical Company Information Table 119. Par Pharmaceutical Business Overview Table 120. Par Pharmaceutical Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 121. Par Pharmaceutical Nanopharmaceuticals Product Portfolio Table 122. Par Pharmaceutical Recent Developments Table 123. Cerulean Pharma Company Information Table 124. Cerulean Pharma Business Overview Table 125. Cerulean Pharma Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 126. Cerulean Pharma Nanopharmaceuticals Product Portfolio Table 127. Cerulean Pharma Recent Developments Table 128. Navidea Biopharmaceuticals Company Information Table 129. Navidea Biopharmaceuticals Business Overview Table 130. Navidea Biopharmaceuticals Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 131. Navidea Biopharmaceuticals Nanopharmaceuticals Product Portfolio Table 132. Navidea Biopharmaceuticals Recent Developments Table 133. Lummy Company Information Table 134. Lummy Business Overview Table 135. Lummy Nanopharmaceuticals Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 136. Lummy Nanopharmaceuticals Product Portfolio Table 137. Lummy Recent Developments Table 138. Global Nanopharmaceuticals Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 139. Global Nanopharmaceuticals Sales by Region (2021-2026) & (K MT) Table 140. Global Nanopharmaceuticals Sales Market Share by Region (2021-2026) Table 141. Global Nanopharmaceuticals Sales by Region (2027-2032) & (K MT) Table 142. Global Nanopharmaceuticals Sales Market Share by Region (2027-2032) Table 143. Global Nanopharmaceuticals Revenue by Region (2021-2026) & (US$ Million) Table 144. Global Nanopharmaceuticals Revenue Market Share by Region (2021-2026) Table 145. Global Nanopharmaceuticals Revenue by Region (2027-2032) & (US$ Million) Table 146. Global Nanopharmaceuticals Revenue Market Share by Region (2027-2032) Table 147. North America Nanopharmaceuticals Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. North America Nanopharmaceuticals Sales by Country (2021-2026) & (K MT) Table 149. North America Nanopharmaceuticals Sales by Country (2027-2032) & (K MT) Table 150. North America Nanopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 151. North America Nanopharmaceuticals Revenue by Country (2027-2032) & (US$ Million) Table 152. Europe Nanopharmaceuticals Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Europe Nanopharmaceuticals Sales by Country (2021-2026) & (K MT) Table 154. Europe Nanopharmaceuticals Sales by Country (2027-2032) & (K MT) Table 155. Europe Nanopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 156. Europe Nanopharmaceuticals Revenue by Country (2027-2032) & (US$ Million) Table 157. Asia Pacific Nanopharmaceuticals Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Asia Pacific Nanopharmaceuticals Sales by Country (2021-2026) & (K MT) Table 159. Asia Pacific Nanopharmaceuticals Sales by Country (2027-2032) & (K MT) Table 160. Asia Pacific Nanopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 161. Asia Pacific Nanopharmaceuticals Revenue by Country (2027-2032) & (US$ Million) Table 162. South America Nanopharmaceuticals Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. South America Nanopharmaceuticals Sales by Country (2021-2026) & (K MT) Table 164. South America Nanopharmaceuticals Sales by Country (2027-2032) & (K MT) Table 165. South America Nanopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 166. South America Nanopharmaceuticals Revenue by Country (2027-2032) & (US$ Million) Table 167. Middle East and Africa Nanopharmaceuticals Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. Middle East and Africa Nanopharmaceuticals Sales by Country (2021-2026) & (K MT) Table 169. Middle East and Africa Nanopharmaceuticals Sales by Country (2027-2032) & (K MT) Table 170. Middle East and Africa Nanopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 171. Middle East and Africa Nanopharmaceuticals Revenue by Country (2027-2032) & (US$ Million) Table 172. Global Nanopharmaceuticals Sales by Type (2021-2026) & (K MT) Table 173. Global Nanopharmaceuticals Sales by Type (2027-2032) & (K MT) Table 174. Global Nanopharmaceuticals Sales Market Share by Type (2021-2026) Table 175. Global Nanopharmaceuticals Sales Market Share by Type (2027-2032) Table 176. Global Nanopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 177. Global Nanopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 178. Global Nanopharmaceuticals Revenue Market Share by Type (2021-2026) Table 179. Global Nanopharmaceuticals Revenue Market Share by Type (2027-2032) Table 180. Global Nanopharmaceuticals Price by Type (2021-2026) & (USD/MT) Table 181. Global Nanopharmaceuticals Price by Type (2027-2032) & (USD/MT) Table 182. Global Nanopharmaceuticals Sales by Application (2021-2026) & (K MT) Table 183. Global Nanopharmaceuticals Sales by Application (2027-2032) & (K MT) Table 184. Global Nanopharmaceuticals Sales Market Share by Application (2021-2026) Table 185. Global Nanopharmaceuticals Sales Market Share by Application (2027-2032) Table 186. Global Nanopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 187. Global Nanopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 188. Global Nanopharmaceuticals Revenue Market Share by Application (2021-2026) Table 189. Global Nanopharmaceuticals Revenue Market Share by Application (2027-2032) Table 190. Global Nanopharmaceuticals Price by Application (2021-2026) & (USD/MT) Table 191. Global Nanopharmaceuticals Price by Application (2027-2032) & (USD/MT) Table 192. Key Raw Materials Table 193. Raw Materials Key Suppliers Table 194. Nanopharmaceuticals Distributors List Table 195. Nanopharmaceuticals Customers List Table 196. Nanopharmaceuticals Industry Trends Table 197. Nanopharmaceuticals Industry Drivers Table 198. Nanopharmaceuticals Industry Restraints Table 199. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Nanopharmaceuticals Product Image Figure 5. Global Nanopharmaceuticals Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Nanopharmaceuticals Market Size (2021-2032) & (US$ Million) Figure 7. Global Nanopharmaceuticals Sales (2021-2032) & (K MT) Figure 8. Global Nanopharmaceuticals Average Price (USD/MT) & (2021-2032) Figure 9. Liposomes Product Image Figure 10. Polymeric Micelles Product Image Figure 11. Solid Lipid Nanoparticles Product Image Figure 12. Microemulsion and Nnanoemulsion Product Image Figure 13. Nanosuspension Product Image Figure 14. Cancer and Tumor Product Image Figure 15. Autoimmune Disorders Product Image Figure 16. Inflammation Product Image Figure 17. Others Product Image Figure 18. Global Nanopharmaceuticals Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Nanopharmaceuticals, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Nanopharmaceuticals Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Nanopharmaceuticals Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Nanopharmaceuticals Sales by Region in 2025 Figure 24. Global Nanopharmaceuticals Revenue by Region in 2025 Figure 25. North America Nanopharmaceuticals Market Size by Country in 2025 Figure 26. North America Nanopharmaceuticals Sales Market Share by Country (2021-2032) Figure 27. North America Nanopharmaceuticals Revenue Market Share by Country (2021-2032) Figure 28. United States Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Nanopharmaceuticals Market Size by Country in 2025 Figure 32. Europe Nanopharmaceuticals Sales Market Share by Country (2021-2032) Figure 33. Europe Nanopharmaceuticals Revenue Market Share by Country (2021-2032) Figure 34. Germany Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Nanopharmaceuticals Market Size by Country in 2025 Figure 45. Asia Pacific Nanopharmaceuticals Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Nanopharmaceuticals Revenue Market Share by Country (2021-2032) Figure 47. China Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Nanopharmaceuticals Market Size by Country in 2025 Figure 56. South America Nanopharmaceuticals Sales Market Share by Country (2021-2032) Figure 57. South America Nanopharmaceuticals Revenue Market Share by Country (2021-2032) Figure 58. Brazil Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Nanopharmaceuticals Market Size by Country in 2025 Figure 62. Middle East and Africa Nanopharmaceuticals Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Nanopharmaceuticals Revenue Market Share by Country (2021-2032) Figure 64. Egypt Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Nanopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Nanopharmaceuticals Sales Market Share by Type (2021-2032) Figure 70. Global Nanopharmaceuticals Revenue Market Share by Type (2021-2032) Figure 71. Global Nanopharmaceuticals Price (USD/MT) by Type (2021-2032) Figure 72. Global Nanopharmaceuticals Sales Market Share by Application (2021-2032) Figure 73. Global Nanopharmaceuticals Revenue Market Share by Application (2021-2032) Figure 74. Global Nanopharmaceuticals Price (USD/MT) by Application (2021-2032) Figure 75. Nanopharmaceuticals Value Chain Figure 76. Nanopharmaceuticals Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Nanopharmaceuticals Industry Opportunities and Challenges

提及公司

MerckPfizerNovartisAbbottGlaxoSmithKlineRocheSanofiEli LillyAstrazenecaJohnson & JohnsonCelgeneNovavaxStrykerGilead SciencesOSI PharmaceuticalsKadmon PharmaceuticalsSamyang BiopharmMitsubishi PharmaKaken PharmaceuticalSelecta BiosciencesPar PharmaceuticalCerulean PharmaNavidea BiopharmaceuticalsLummy

量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們